Allogeneic stem cell transplantation in chronic myeloid leukaemia--2 1/2 year experience
- PMID: 16304866
Allogeneic stem cell transplantation in chronic myeloid leukaemia--2 1/2 year experience
Abstract
Objective: To evaluate out come of allogeneic Stem Cell Transplantation (SCT) in chronic myeloid leukaemia (CMC) at Armed Forces Bone Marrow Transplant Centre, Rawalpindi from April 2002 to October 2004.
Methods: Twenty-two patients with CML underwent allogeneic SCT from HLA matched siblings. Patients were divided into standard (n=14) and high-risk (n=8) groups. Patients were subjected to conditioning regimens consisting of Busulphan and Cyclophosphamide. Cyclosporin, Prednisolone and Methotrexate were given for GvHD prophylaxis. All donors were subjected to PBSC harvest after G-CSF therapy for five days. All received G-CSF from Day+5 until ANC >0.5 x 10(9)/l.
Results: The median age of the patients was 29 years (range 7-53 years) with a male to female ratio of 6.3:1. Engraftment was achieved in all patients. Median time to achieve neutrophil (ANC 0.5 x 10(9)/l) and platelet (20 x 10(9)/l) recovery was 13 days and 12 days respectively. Median stay in hospital was 18 days. Acute GvHD (Grade-II-IV) was observed in eleven patients (50%) while chronic GvHD was seen in four patients (18%). One patient relapsed 8 months post transplant. Two patients (9%) developed Veno-occlusive disease (VOD) liver. One patient had haemorrhagic cystitis. Four patients (18%) had post transplant infectious complications, which included pseudomonas septicemia, aspergillosis, tuberculous pleural effusion and herpes zoster. Overall mortality was 22.7% (n=5). The major causes of mortality were VOD liver, GvHD grade IV, Pseudomonas septicaemia and aspergillosis. Overall survival was 77.2% (n=17) and disease free survival was (n=16) 72.7%. Follow up ranges were from 23 to 828 days (median 212 days).
Conclusion: The preliminary results of SCT in this small series of patients with CML are very encouraging. To improve the long-term survival it is imperative that patients are transplanted early after diagnosis and conditioning regimens are selected carefully.
Similar articles
-
Allogeneic stem cell transplantation in chronic myeloid leukemia two and a half year experience.Turk J Haematol. 2005 Jun 5;22(2):79-86. Turk J Haematol. 2005. PMID: 27264665 English.
-
Post-transplant outcome in chronic myeloid leukaemia.J Coll Physicians Surg Pak. 2008 Oct;18(10):615-9. doi: 10.2008/JCPSP.615619. J Coll Physicians Surg Pak. 2008. PMID: 18940118
-
Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.Anticancer Res. 1997 Jan-Feb;17(1B):589-99. Anticancer Res. 1997. PMID: 9066585
-
Allogeneic bone marrow transplantation in beta-thalassaemia--single centre study.J Pak Med Assoc. 2004 Oct;54(10):499-503. J Pak Med Assoc. 2004. PMID: 15552281 Clinical Trial.
-
Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.Haematologica. 1998 Jan;83(1):48-55. Haematologica. 1998. PMID: 9542323 Clinical Trial.
Cited by
-
Outcome of allogeneic hematopoietic stem cell transplantation in patients with hematological malignancies.Int J Hematol Oncol Stem Cell Res. 2014 Oct 1;8(4):30-8. Int J Hematol Oncol Stem Cell Res. 2014. PMID: 25774265 Free PMC article.
MeSH terms
LinkOut - more resources
Medical
Research Materials
Miscellaneous